Pharmacoeconomic Evaluation in Generalized Anxiety Disorder: A North India Perspective
Keywords:
Pharmacoeconomics, Pharmacoeconomic analysis, Cost effectiveness, Cost of illness, Generalised anxiety disorderAbstract
Background: The most prevalent mental disorder is anxiety disorders. A common type of anxiety disorder is generalised anxiety disorder (GAD). Objectives of the study were to evaluate cost of illness (COI) and cost effectiveness of different pharmacological treatments in patients with GAD.
Methods: This was a single centred prospective observational study. The duration of the study was one year. The inclusion criteria were patients with GAD, both male and female patients, patients within 18-60 years age group, and willingness to participate.
Results: A total of 352 patients were analysed in the study. Escitalopram, venlafaxine XR and paroxetine were the drugs used as the treatment option for GAD patients. Quality-Adjusted Life Year (QALY) gained for paroxetine was found to be highest, followed by venlafaxine XR and escitalopram. Cost effectiveness of escitalopram, venlafaxine XR and paroxetine for GAD were found to be 3395, 4655, and 8554 ₹/QALY gained respectively. The COI attributable to GAD for six months was estimated ₹29945. Indirect costs constituted 70% of total costs whereas pharmacotherapy accounted for 22.5% of the COI. The contribution of absenteeism cost was 45.2% of the COI.
Conclusion: Escitalopram is found to be cost effective compared with venlafaxine XR and paroxetine for the treatment of GAD. GAD shows significant economic burden as COI was significant around thirty thousand Indian rupees.
Downloads
References
Aucoin M, LaChance L, Naidoo U, Remy D, Shekdar T, Sayar N, Cardozo V, Rawana T, Chan I, Cooley K. Diet and Anxiety: A Scoping Review. Nutrients. 2021 Dec 10;13(12):4418. Available from: https://doi.org/10.3390/nu13124418
Gomez AF, Barthel AL, Hofmann SG. Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review. Expert Opin Pharmacother. 2018 Jun;19(8):883-94. Available from: https://doi.org/10.1080/14656566.2018.1472767
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000:429-84.
Mendlowicz MV, Stein MB. Quality of life in individuals with anxiety disorders. Am J Psychiatry. 2000 May;157(5):669-82. Available from: https://doi.org/10.1176/appi.ajp.157.5.669
Manjunatha N, Jayasankar P, Suhas S, Rao GN, Gopalkrishna G, Varghese M, Benegal V; NMHS National Collaborators Group. Prevalence and its correlates of anxiety disorders from India's National Mental Health Survey 2016. Indian J Psychiatry. 2022 Mar-Apr;64(2):138-42.
Goodman WK. Selecting pharmacotherapy for generalized anxiety disorder. J Clin Psychiatry. 2004;65(Suppl 13):8-13.
Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU; British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005 Nov;19(6):567-96. Available from: https://doi.org/10.1177/0269881105059253
DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy A Pathophysiologic Approach. 7th ed. New York: McGraw-Hill; 2008.
Rickels K, Rynn M. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry. 2002;63 Suppl 14:9-16.
Shargel L. Comprehensive pharmacy review. 7th ed. Baltimore: Lippincott Williams & Wilkins; 2009.
Rascati KL. Essentials of Pharmacoeconomics. 2nd ed. Philadelphia: Lippincott Williams and Wilkins; 2014.
Luce BR, Simpson K. Methods of cost-effectiveness analysis: areas of consensus and debate. Clin Ther. 1995 Jan-Feb;17(1):109-25.
Widera E, Chang A, Chen HL. Presenteeism: a public health hazard. J Gen Intern Med. 2010 Nov;25(11):1244-7.
Oral B, Solak Y, Durmuş H. Evaluation of absenteeism and presenteeism status of factory employees. Work. 2024;79(1):449-57. Available from: https://doi.org/10.3233/WOR-230642
Sampogna F, Mastroeni S, Pallotta S, Fusari R, Uras C, Napolitano M, Abeni D. Use of the SF-12 questionnaire to assess physical and mental health status in patients with psoriasis. J Dermatol. 2019 Dec;46(12):1153-59. Available from: https://doi.org/10.1111/1346-8138.15074
Shaw LJ. Cost-Effectiveness of Myocardial Perfusion Single-Photon Emission Computed Tomography. In: Zaret BL, Beller GA, editors. Clinical Nuclear Cardiology: State of the Art and Future Directions. Philadelphia: Mosby; 2010. p. 400-12.
Bang H, Zhao H. Median-Based Incremental Cost-Effectiveness Ratio (ICER). J Stat Theory Pract. 2012;6(3):428-42. Available from: https://doi.org/10.1080/15598608.2012.695571
Dimoliatis ID. Standardised QALYs and DALYs are more understandable, avoid misleading units of measurement, and permit comparisons. J Epidemiol Community Health. 2004 Apr;58(4):354.
Zhang J, Xu H, Chen Z. Pharmacoeconomic evaluation of venlafaxine compared with citalopram in generalized anxiety disorder. Exp Ther Med. 2013 Mar;5(3):840-44. Available from: https://doi.org/10.3892/etm.2012.869
Iskedjian M, Walker JH, Bereza BG, Le Melledo JM, Einarson TR. Cost-effectiveness of escitalopram for generalized anxiety disorder in Canada. Curr Med Res Opin. 2008 May;24(5):1539-48. Available from: https://doi.org/10.1185/030079908X297277
Jørgensen TR, Stein DJ, Despiegel N, Drost PB, Hemels ME, Baldwin DS. Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom. Ann Pharmacother. 2006 Oct;40(10):1752-8. Available from: https://doi.org/10.1345/aph.1H156
Rovira J, Albarracin G, Salvador L, Rejas J, Sánchez-Iriso E, Cabasés JM. The cost of generalized anxiety disorder in primary care settings: results of the ANCORA study. Community Ment Health J. 2012 Jun;48(3):372-83.
Bereza BG, Machado M, Papadimitropoulos M, Sproule B, Ravindran AV, Einarson TR. A markov model approach assessing the cost of illness of generalized anxiety disorder in Canada. Neurol Ther. 2012 Jun 7;1(1):1.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
